BRIC Diabetes Treatment Prevention Companies

Dec 2023Novo Nordisk Launched their FlexTouch® insulin pen with an improved needle design in all BRIC countries, enhancing patient comfort and injection experience.Partnered with local healthcare organizations to improve insulin access and diabetes education in rural areas.

Eli Lilly and Company Received regulatory approval for their Trulicity® GLP-1 agonist in additional BRIC markets, expanding access to this long-acting medication.Collaborated with digital health startups to develop AI-powered tools for diabetes management and patient support.

Sanofi S.A. Introduced their SoloStar® pen with pre-filled insulin cartridges in different insulin types across BRIC countries, offering convenience and flexibility for patients.Focused on developing affordable insulin formulations and pricing strategies for wider accessibility.

Medtronic Launched their MiniMed™ 670G system with integrated insulin pen connectivity in India, allowing for automated insulin delivery based on continuous glucose monitoring data.Partnered with government agencies to provide diabetes management technologies and training programs in remote regions.

Johnson & Johnson Expanded access to their Canagliflozin SGLT-2 inhibitor medication in Brazil and Russia, offering a new treatment option for diabetes management.Invested in research and development of novel diabetes medications and technologies tailored for the specific needs of BRIC populations.

List of BRIC Diabetes Treatment and Prevention Key Companies in the Market

• Abbott Laboratories (U.S)


• Bayer AG (Germany)


• Eli Lily & Company (U.S)


• Medtronic (U.S)


• AstraZeneca Plc. (U.K)


• Lifescan (U.S)


• Terumo Medical Corporation (Japan)


• Roche Holding AG (Switzerland)